<DOC>
	<DOCNO>NCT02253394</DOCNO>
	<brief_summary>The purpose study find spironolactone added ambrisentan Pulmonary Arterial Hypertension ( PAH ) increase exercise capacity . We also want find spironolactone ambrisentan effect cardiac output ( amount blood heart pump every minute ) , right ventricle function quality life .</brief_summary>
	<brief_title>The Combination Ambrisentan Plus Spironolactone Pulmonary Arterial Hypertension Study</brief_title>
	<detailed_description>A prospective , double blind , placebo-controlled clinical study involve 30 patient World Health Organization ( WHO ) Group 1 pulmonary arterial hypertension treat ambrisentan randomized receive placebo spironolactone ( 50 mg/d ) 90 day use cross-over trial design . Eligible participant randomize receive placebo spironolactone ( 50 mg/d ) 90 day ( Phase I ) . At completion Phase I , participant undergo repeat end-point assessment follow 21-day drug washout period . Then , 90 day crossover phase trial occur ( Phase II ) , participant randomize placebo Phase I treat spironolactone ( 50 mg/d ) Phase II vice versa . At conclusion Phase II , end-point measure reassess . Spironolactone diuretic use treatment PAH patient . Spironolactone usually add medical treatment dos Lasix/Torsemide increase patient risk hypokalemia . Study procedures do research study standard procedure perform PAH patient clinic follow-up except Cardiopulmonary Exercise Test ( CPET ) Innocor .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>1 . Voluntarily give informed consent participate study . 2 . Right heart catheterization demonstrate conventional mean pulmonary artery pressure ( mPAP ) &gt; 25 , pulmonary vascular resistance ( PVR ) &gt; 3.0 Wood Units , pulmonary capillary wedge pressure ( PCWP ) &lt; 16 mmHg within one year enrollment 3 . Subject 1675 year age Screening . 4 . Diagnosis symptomatic idiopathic heritable PAH , PAH associate Connective Tissue Disease ( CTD ) , PAH associate repaired/unrepaired congenital systemictopulmonary shunt , Portopulmonary hypertension PAH associate HIV infection . 5 . New York Heart Association Functional Class II III 6 . Stable therapy ambrisentan 5 10 mg every day &gt; 90 day . 7 . Baseline 6Minute Walk Distance 50450m 1 . Substantial Primary Lung disease force expiratory volume one second ( FEV1 ) /forced vital capacity ( FVC ) &lt; 0.6 FEV1 &lt; 70 % predict diffusing capacity lung carbon monoxide ( DLCO ) &lt; 30 % predict Pulmonary fibrosis 2 . Left ventricular ejection fraction &lt; 50 % 3 . Pulmonary capillary wedge pressure &gt; 16 mm Hg 4 . Aortic valve disease 5 . Ischemic heart disease 6 . Systemic hypotension ( SBP &lt; 90 mm Hg ) 7 . Coexisting treatment endothelin receptor antagonists prostacyclin analogue 8 . New York Heart Association Functional Class IV 9 . Chronic thromboembolic pulmonary hypertension 10 . Known suspected pulmonary venoocclusive disease 11 . Serum creatinine &gt; 2.0 mg/dL woman , Serum creatinine &gt; 2.5 mg/dL men 12 . Baseline serum potassium &gt; 5.0 milliequivalent ( mEq ) /L 13 . Participation ongoing drug/interventionbased clinical trial 14 . Pregnancy 15 . Unable provide consent</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Pulmonary Arterial Hypertension ( PAH )</keyword>
	<keyword>Ambrisentan</keyword>
	<keyword>Spironolactone</keyword>
	<keyword>Selective Endothelin A ( ETA ) inhibition</keyword>
	<keyword>Aldosterone antagonism</keyword>
	<keyword>Cardiac output ( CO )</keyword>
	<keyword>Right ventricular ( RV ) function</keyword>
	<keyword>Heart failure</keyword>
	<keyword>Quality life</keyword>
	<keyword>Pro-inflammatory cytokine</keyword>
	<keyword>Interleukin-6 ( IL-6 )</keyword>
	<keyword>Troponin-I</keyword>
	<keyword>N-terminal pro-brain natriuretic peptide ( NT-BNP )</keyword>
	<keyword>Collagen metabolism</keyword>
	<keyword>N-terminal procollagen type I</keyword>
	<keyword>Collagen III</keyword>
	<keyword>Echocardiography</keyword>
	<keyword>WHO Functional Class</keyword>
	<keyword>Cardiopulmonary Exercise Test Innocor</keyword>
	<keyword>Peak oxygen consumption ( pVO2 )</keyword>
	<keyword>Liver function marker ( AST/ALT )</keyword>
	<keyword>Renal function marker ( creatinine potassium )</keyword>
</DOC>